Infiltración ocular en paciente con mieloma múltiple

  1. E Santos-Bueso
  2. C Calvo-González
  3. J Troyano
  4. D Díaz-Valle
  5. M Saiz
  6. JM Benítez-del-Castillo
  7. J García-Sánchez
Journal:
Archivos de la Sociedad Española de Oftalmologia

ISSN: 0365-6691

Year of publication: 2005

Volume: 80

Issue: 12

Pages: 725-728

Type: Article

DOI: 10.4321/S0365-66912005001200008 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Archivos de la Sociedad Española de Oftalmologia

Abstract

Case report: We report the case of a patient with Multiple Myeloma Ig G Kappa stage IIIA and hepatic infiltration, who presented with ocular infiltration. The initial sign was a rapidly growing sub-conjunctival mass that caused ophthalmoplegia and increased intraocular pressure secondary to progressive infiltration of the orbit. Discussion: Multiple Myeloma is a malignant tumor of plasma cells that can affect the eye and orbit, not only as an infiltration secondary to the disease but also primary as an isolated tissue proliferation (extramedullary plasmacytoma). Chemotherapy is the usual treatment given. Radiotherapy with or without excisional surgery is the first option for plasmacytomas.

Bibliographic References

  • Longo, DL, Anderson, KC. (2005). Harrison: Principios de Medicina Interna. 16. McGraW-Hill. México, D.F..
  • Prada Sánchez, MC, Pérez Moreiras, JV, Pérez Encinas, JL, Fraga, M, Corteza, J, Vanegas, P. (2002). Patología Orbitaria. EdikaMed. Barcelona.
  • Palmer, M, Belch, A, Hanson, J, Brox, L. (1988). Dose intensity analysis of melphalan and prednisone in multiple myeloma. J Natl Cancer Inst. 80. 414-418
  • Kyle, RA, Rajkumar, SV. (2004). Multiple myeloma. N Engl J Med. 351. 1860-1873
  • Featherstone, C, Delaney, G, Jacob, S, Barton, M. (2005). Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part II-Leukemia and myeloma. Cancer. 103. 393-401
Data source: Dialnet